BioSpace News Archive

Biomolecular condensates could hold the key to unlocking a number of neurological diseases that have baffled researchers the longest.

Amicus Therapeutics is launching a next-generation genetic medicine company called Caritas Therapeutics, Inc. through a merger deal with ARYA Sciences Acquisition Corp IV.

AstraZeneca’s Alexion plans to buy all remaining equity in Caelum Biosciences and pick up Caelum’s CAEL-101 in the process.

As the 10th annual IDWeek (Infectious Disease Week) Conference begins, treatments aimed at COVID-19 will certainly dominate the program.

The announcement came following independent FDA analyses of inspections conducted at the two CROs in November 2019.

Ascendis Pharma A/S, a biopharmaceutical company that utilizes its innovative TransCon™ technologies to potentially create new treatments that make a meaningful difference in patients’ lives, announced that its Board of Directors has authorized the Company to repurchase up to $25 million of the Company’s American Depositary Shares, each of which represents one ordinary share of Ascendis Pharma A/S.

Insulet Corporation, the global leader in tubeless insulin pump technology with its Omnipod® brand of products, announced plans to release its financial results for the third quarter of 2021 on November 4, 2021 after the close of the financial markets.

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the independent members of the Merck Board of Directors have appointed Thomas H. Glocer as independent lead director effective immediately.

MannKind Corporation, a company focused on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases, announced that it has entered into a sale-leaseback transaction with an affiliate of Creative Manufacturing Properties, which will generate $102.25 million in gross proceeds upon closing.

GENFIT, a late-stage biopharmaceutical company dedicated to improving the lives of patients with metabolic and chronic liver diseases, announced its first half-year financial results and provided a corporate update.